Literature DB >> 15312898

Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture.

M Garcia1, D Charvin, J Caboche.   

Abstract

Huntington's disease (HD) is an autosomal neurodegenerative disorder, caused by expansion of a glutamine repeat in the Huntingtin protein. Pathogenesis in HD includes the cytoplasmic cleavage of Huntingtin and release of an amino-terminal fragment capable of nuclear localization, where expanded-Huntingtin (Exp-Htt) might lead to aberrant transcriptional regulation, neuronal dysfunction and degeneration. Recent evidence, from hippocampal cell lines, also implicates altered interaction of Exp-Htt with components of the c-Jun N-terminal kinase (JNK) cascade. However, there is yet no proven implication of the JNK/c-Jun module in degeneration of striatal neurons, the more vulnerable cell population, in HD. In the present study, we used primary striatal neurons in culture to analyze c-Jun activation by Exp-Htt. Green fluorescent protein (GFP)-tagged exon 1 of human Huntingtin either in its normal (25Q, normal-Htt) or expanded (103Q, Exp-Htt) version was transiently transfected in these cells. We first set out, in our conditions, the time course of striatal degeneration produced by Exp-Htt, and found it occurred rapidly. At 48 h post-transfection, 60% of striatal neurons expressing Exp-Htt had apoptotic characteristics including DNA fragmentation and neuritic retraction. Most of these neurons also showed nuclear aggregates of GFP-Exp Htt. Kinetics of c-Jun activation were tested in transfected cells using immunocytochemical detection of phospho-c-Jun. We found a significant activation and induction of c-Jun in Exp-Htt but not normal-Htt-transfected neurons. Of interest, these events occurred prior to nuclear translocation of Exp-Htt. Finally, overexpression of a dominant negative version of c-Jun, as well as pharmacological inhibition of JNK strongly protected against DNA fragmentation and neuritic retraction induced by Exp-Htt. Thus our data suggest that c-Jun activation and induction, is an early event in the pathogenesis of HD, occurring prior to formation of nuclear aggregates of Exp-Htt.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312898     DOI: 10.1016/j.neuroscience.2004.05.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  CRMP5-associated GTPase (CRAG) protein protects neuronal cells against cytotoxicity of expanded polyglutamine protein partially via c-Fos-dependent activator protein-1 activation.

Authors:  Shun Nagashima; Toshifumi Fukuda; Yuka Kubota; Ayumu Sugiura; Mitsuyoshi Nakao; Ryoko Inatome; Shigeru Yanagi
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

4.  A protein quality control pathway regulated by linear ubiquitination.

Authors:  Eva M van Well; Verian Bader; Maria Patra; Ana Sánchez-Vicente; Jens Meschede; Nikolas Furthmann; Cathrin Schnack; Alina Blusch; Joseph Longworth; Elisabeth Petrasch-Parwez; Kohji Mori; Thomas Arzberger; Dietrich Trümbach; Lena Angersbach; Cathrin Showkat; Dominik A Sehr; Lena A Berlemann; Petra Goldmann; Albrecht M Clement; Christian Behl; Andreas C Woerner; Carsten Saft; Wolfgang Wurst; Christian Haass; Gisa Ellrichmann; Ralf Gold; Gunnar Dittmar; Mark S Hipp; F Ulrich Hartl; Jörg Tatzelt; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2019-03-18       Impact factor: 11.598

5.  Preventing polyglutamine-induced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy.

Authors:  Karine Merienne; James Friedman; Masayuki Akimoto; Gretta Abou-Sleymane; Chantal Weber; Anand Swaroop; Yvon Trottier
Journal:  Neurobiol Dis       Date:  2006-12-26       Impact factor: 5.996

6.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

7.  Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type.

Authors:  Samia Hannaoui; Layal Maatouk; Nicolas Privat; Etienne Levavasseur; Baptiste A Faucheux; Stéphane Haïk
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

8.  Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced Huntington's-Like Symptoms.

Authors:  Minhee Jang; Min Jung Lee; Cheon Suk Kim; Ik-Hyun Cho
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-27       Impact factor: 2.629

9.  Huntington's Disease and Striatal Signaling.

Authors:  Emmanuel Roze; Emma Cahill; Elodie Martin; Cecilia Bonnet; Peter Vanhoutte; Sandrine Betuing; Jocelyne Caboche
Journal:  Front Neuroanat       Date:  2011-08-23       Impact factor: 3.856

10.  Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin.

Authors:  Gerardo A Morfini; Yi-Mei You; Sarah L Pollema; Agnieszka Kaminska; Katherine Liu; Katsuji Yoshioka; Benny Björkblom; Eleanor T Coffey; Carolina Bagnato; David Han; Chun-Fang Huang; Gary Banker; Gustavo Pigino; Scott T Brady
Journal:  Nat Neurosci       Date:  2009-06-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.